| Field | Specification |
|---|---|
| Target | |
| Antigen | |
| Alternative names | KIAA0439, NEDL3 |
| Gene ID | |
| Host | |
| Clone | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | polypeptide |
| Conjugate | |
| Molecular weight | |
| Purification | |
| Cellular localization | |
| Formulation | |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
U-Blot® Phospho-NEDD4L (Ser448) Rabbit mAb is a recombinant monoclonal antibody raised in Rabbit that specifically recognizes Phospho-NEDD4L (Ser448) (Phosphorylation [Ser448]). It is designed for detection and analysis of the Phosphorylation [Ser448] post-translational modification across research applications.
NEDD4 and NEDD4-like (NEDD4L) proteins contain multiple functional domains including a calcium-dependent phospholipid and membrane binding domain (C2 domain), two to four protein binding domains (WW domains), and an E3 ubiquitin-protein ligase domain (HECT domain). NEDD4 and NEDD4L have been shown to downregulate both neuronal voltage-gated Na+ channels (NaVs) and epithelial Na+ channels (ENaCs) in response to increased intracellular Na+ concentrations. The WW domains of NEDD4 bind to PY motifs (amino acid sequence PPXY) found in multiple NaV and ENaC proteins; ubiquitination of these proteins is mediated by the HECT domain of NEDD4 and results in their internalization and removal from the plasma membrane. Research studies have shown that mutation of the PY motifs in ENaC proteins is associated with Liddle's syndrome, an autosomal dominant form of hypertension. In addition to targeting sodium channels, NEDD4L has also been shown to negatively regulate TGF-β signaling by targeting Smad2 for degradation. Mouse and human NEDD4 are rapidly cleaved by caspase proteins during apoptosis, although the significance of this cleavage is not clear.NEDD4L can be phosphorylated at Ser342 and Ser448 by several AGC kinase family members including SGK1, Akt, and PKA. Phosphorylation at these sites inhibits NEDD4L function as a suppressor of ENaCs and as a regulator of TGF-β signaling through its effects on Smad2/3 binding.
Validated Applications
| Application | Western Blot |
|---|---|
| Recommended Dilution | WB 1:1000 |
| Host | Rabbit |
| Clonality | Recombinant Monoclonal |
| Isotype | IgG |
| Reactivity | Human |
| Conjugate | Unconjugated |
| Purification | Protein A |
| Molecular Weight | Calculated: 112 kDa | Observed: 120 kDa |
Immunogen / Antigen
polypeptide
Reactivity Notes
This antibody shows reactivity with Human. It targets the Phosphorylation [Ser448] modification and is suitable for Western Blot.
Safety & Handling
Related Products
Explore other UcallM Biosciences post-translational modification antibodies available through BioHippo.
It is validated for Western Blot. Recommended dilutions: WB 1:1000.
Use WB 1:1000. Optimal dilution should be determined empirically for your sample and detection system.
This is a pan-modification antibody recognizing Phospho-NEDD4L (Ser448) (Phosphorylation [Ser448]); reactivity: Human.
The recombinant monoclonal antibody (Rabbit host) was raised against polypeptide.
This product is supplied unconjugated. Contact BioHippo for custom conjugation or format options.
Store at -20°C. Avoid repeated freeze-thaw cycles | Stable for 12 months from date of receipt / reconstitution.
Customization & Add-ons: Can't find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
